Allogeneic hematopoietic stem cell transplantation against recurrent rhabdomyosarcoma

Journal of Pediatric Hematology/Oncology

Volumn 33, Issue 1, 2011, Pages

  Ohta, Hideaki ^a   Hashii, Yoshiko ^a   Yoshida, Hisao ^a   Kusuki, Shigenori ^a   Tokimasa, Sadao ^a   Yoneda, Akihiro ^a   Fukuzawa, Masahiro ^a   Inoue, Nami ^b   Hara, Junichi ^c   Kusafuka, Takeshi ^d   Ozono, Keiichi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

^c OSAKA CITY GENERAL HOSPITAL   (Japan)

^d NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Allogeneic; graft versus tumor effect; hematopoietic stem cell transplantation; rhabdomyosarcoma

Indexed keywords

BUSULFAN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; IFOSFAMIDE; MELPHALAN; METHOTREXATE; PIRARUBICIN; PREDNISOLONE; TACROLIMUS; THIOTEPA; TOPOTECAN; VINCRISTINE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER REGRESSION; CASE REPORT; CHILD; DONOR LYMPHOCYTE INFUSION; FEMALE; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; IMMUNOCOMPETENT CELL; LYMPH NODE METASTASIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; RHABDOMYOSARCOMA; TUMOR BIOPSY;

CHILD; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; PROGNOSIS; RECURRENCE; RHABDOMYOSARCOMA, ALVEOLAR; TRANSPLANTATION, HOMOLOGOUS;

EID: 78650762985     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181e7ddc5     Document Type: Article

References (27)

1. Stevens MC, Rey A, Bouvet N, et al. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: Third study of the International Society of Paediatric Oncology-SIOP Malignant Mesenchymal Tumor 89. J Clin Oncol. 2005;23:2618-2628.
2. Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol. 1995;13:610-630.
3. Pappo AS, Anderson JR, Crist WM, et al. Survival after relapse in children and adolescents with rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group. J Clin Oncol. 1999;17:3487-3493.
4. Breneman JC, Lyden E, Pappo AS, et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma-A report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol. 2003;21:78-84.
5. Hara J, Osugi Y, Ohta H, et al. Double-conditioning regimens consisting of thiotepa, melphalan and busulfan with stem cell rescue for the treatment of pediatric solid tumors. Bone Marrow Transplant. 1998;22:7-12.
6. Carli M, Colombatti R, Oberlin O, et al. European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: Final results and analysis of prognostic factors. J Clin Oncol. 2004;22:4787-4794.
7. Weigel BJ, Breitfeld PP, Hawkins D, et al. Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma. J Pediatr Hematol Oncol. 2001;23:272-276.
8. Porter D, Levine JE. Graft-versus-host disease and graftversus- leukemia after donor leukocyte infusion. Semin Hematol. 2006;43:53-61.
9. Ueno NT, Cheng YC, Rondó n G, et al. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood. 2003;102:3829-3836.
10. Lundqvist A, Childs R. Allogeneic hematopoietic cell transplantation as immunotherapy for solid tumors: Current status and future directions. J Immunother. 2005;28:281-288.
11. Demirer T, Barkholt L, Blaise D, et al. Transplantation of allogeneic hematopoietic stem cells: An emerging treatment modality for solid tumors. Nat Clin Pract Oncol. 2008;5: 256-267.
12. Dalerba P, Frascella E, Macino B, et al. MAGE, BAGE and GAGE gene expression in human rhabdomyosarcomas. Int J Cancer. 2001;93:85-90.
13. Rodeberg DA, Erskine C, Celis E. In vitro induction of immune responses to shared tumor-associated antigens in rhabdomyosarcoma. J Pediatr Surg. 2007;42:1396-1402.
14. Doelken R, Weigel S, Schueler F, et al. Poor outcome of two children with relapsed state stage IV alveolar rhabdomyosarcoma after allogeneic stem cell transplantation. Pediatr Hematol Oncol. 2005;22:699-703.
15. Misawa A, Hosoi H, Tsuchiya K, et al. Regression of refractory rhabdomyosarcoma after allogeneic stem-cell transplantation. Pediatr Hematol Oncol. 2003;20:151-155.
16. Donker AE, Hoogerbrugge PM, Mavinkurve-Groothuis AMC, et al. Metastatic rhabdomyosarcoma cured after chemotherapy and allogeneic SCT. Bone Marrow Transplant. 2009; 43:179-180.
17. Ogawa H, Ikegame K, Yoshihara S, et al. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. Biol Blood Marrow Transplant. 2006;12:1073-1084.
18. Yoshihara T, Okada K, Kobayashi M, et al. Outcome of non- T-cell-depleted HLA-haploidentical hematopoietic stem cell transplantation from family donors in children and adolescents. Int J Hematol. 2007;85:246-255.
19. Oh H, Loberiza FR Jr, Zhang MJ, et al. Comparison of graftversus- host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. Blood. 2005;105:1408-1416.
20. Tomblyn M, Lazarus HM. Donor lymphocyte infusions: The long and winding road: How should it be traveled? Bone Marrow Transplant. 2008;42:569-579.
21. Saylors RL III, Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: A Pediatric Oncology Group phase II study. J Clin Oncol. 2001;19:3463-3469.
22. Wells RJ, Reid JM, Ames MM, et al. Phase I trial of cisplatin and topotecan in children with recurrent solid tumors: Children's Cancer Group Study 0942. J Pediatr Hematol Oncol. 2002;24:89-93.
23. Walterhouse DO, Lyden ER, Breitfeld PP, et al. Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: A Children's Oncology Group study. J Clin Oncol. 2004;22:1398-1403.
24. Meazza C, Casanova M, Zaffignani E, et al. Efficacy of topotecan plus vincristine and doxorubicin in children with recurrent/refractory rhabdomyosarcoma. Med Oncol. 2009;26:67-72.
25. Rowinsky EK, Kaufmann SH, Baker SD, et al. A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia. Clin Cancer Res. 1996;2:1921-1930.
26. Furman WL, Stewart CF, Kirstein M, et al. Protracted intermittent schedule of topotecan in children with refractory acute leukemia: A pediatric oncology group study. J Clin Oncol. 2002;20:1617-1624.
27. Houghton JA, Houghton PJ, Green AA. Chemotherapy of childhood rhabdomyosarcomas growing as xenografts in immune-deprived mice. Cancer Res. 1982;42:535-539.